WASHINGTON – The Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF), today released the HRS/ACCF Expert Consensus Statement on Pacemaker Device and Mode Selection.The expert consensus statement was developed in collaboration with the Society of Thoracic Surgeons, endorsed by the American Heart Association, and published online today as part of the August edition of HeartRhythm, the official journal of the Heart Rhythm Society, as well as the Journal of the American College of Cardiology. The statement is the first of its kind to specifically address pacemaker device and mode selection, expanding upon the ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities.
Search for "" returned 192 matches
WASHINGTON, DC — New research shows magnetic interference from portable headphones has a clinically significant impact on the function of life-saving devices, according to a new study published in the October edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society. The study is the largest and most complete of its kind and uncovers a need for greater dialogue between doctors and patients with implanted cardioverter-defibrillators (ICDs) and pacemakers.
WASHINGTON, DC —More than 250,000 deaths occur each year as a result of sudden cardiac arrest (SCA). In fact, SCA claims one life every two minutes, taking more lives each year than breast cancer, lung cancer or AIDS. Yet, according to a recent survey issued by the Heart Rhythm Society, more than 70 percent of Americans not only underestimate the seriousness of SCA, but also believe SCA is a type of heart attack.
WASHINGTON, DC — New findings shed light on the burden of sudden cardiac arrest (SCA) among children and suggest additional research may lead to better prediction and prevention of sudden death, according to a study published in the November edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society.
WASHINGTON, DC — New findings indicate reduced heart rate recovery in combination with heightened T-wave alternans is a powerful predictor of cardiovascular and all-cause death in low-risk populations. The study, published in the December edition of the HeartRhythm Journal, reveals routine exercise testing could allow health professionals to assess cardiovascular mortality based on the measurement of heart rate recovery and T-wave alternans.
WASHINGTON, DC — The American College of Cardiology (ACC) and Heart Rhythm Society (HRS) announce a new collaboration to build and deliver innovative programs and resources for cardiology clinicians treating patients with atrial fibrillation (AF).
WASHINGTON, April 1, 2010 — New findings confirm atrial fibrillation (AF) is independently associated with the risk of all forms of dementia, including Alzheimer’s and other senile and vascular dementia types. According to a study published in the April edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, the presence of atrial fibrillation indicated higher mortality rates in all dementia subtypes; however, mortality risk was most prominent in the youngest population studied.
WASHINGTON, DC — The International Board of Heart Rhythm Examiners (IBHRE) has received five-year accreditation from the American National Standards Institute (ANSI) under ANSI/ISO/IEC 17024 for Personnel Certification Bodies.
DENVER, May 13, 2010 – According to a sub-study of the Multicenter Automatic Defibrillator Implantation Trial-CRT (MADIT-CRT), left ventricular (LV) leads positioned in the apical region when compared to the mid-ventricular or basal regions are associated with a significantly increased risk of heart failure (HF) and death in patients receiving cardiac resynchronization therapy (CRT). The late-breaking clinical trial presented today at Heart Rhythm 2010, the Heart Rhythm Society’s 31st Annual Scientific Sessions, is the first trial to evaluate clinical outcomes based on the LV lead position within a mildly symptomatic CRT patient population.
Dallas — The newly approved drug dabigatran is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation, according to updated guidelines from the American College of Cardiology, American Heart Association and the Heart Rhythm Society.